Incidence and predictors of heart failure among anthracycline-treated older adults with lymphoma
Anthracycline-based chemotherapy is recommended in diffuse large B-cell lymphoma (DLBCL) and classic Hodgkin lymphoma (cHL) but can cause heart failure (HF), especially in older patients who have increased risk due to age and comorbidities. To estimate the risk of incident HF in older DLBCL or cHL patients. Using SEER-Medicare, we identified individuals 65 years of age and older diagnosed with DLBCL or cHL between 2000–2015 who received anthracycline-containing therapy and were free of preexisting HF. Incident HF and HF hospitalization were ascertained from billing codes using validated algorithms. Separate multivariate risk prediction models were developed for the outcomes of 1) incident HF and 2) HF hospitalization using Fine and Gray models that account for the competing risk of death. Among 13,401 individuals with newly diagnosed DLBCL or cHL (mean age 75.1 ± 6.1 years, 49.1% female), we observed 3,343 incident HF diagnoses over a median (IQR) follow-up of 2.7 (0.8, 6.1) years. Two and 5-year estimates of incident HF diagnoses after anthracycline were 14.2% (95% CI 13.6–14.8%) and 21.6% (95% CI 20.9–22.3%), respectively, and 2-year cumulative incidence of HF hospitalization was 9.6% (95% CI 9.1–10.1%) in models accounting for the competing risk of death. Older age, cHL diagnosis, hypertension, diabetes, coronary artery disease, atrial fibrillation, valvular heart disease, chronic obstructive pulmonary disease and peripheral vascular disease were associated with higher incident HF. The optimism-corrected c-statistic was 0.60 (95% CI 0.59, 0.61). Incident HF occurred in more than 14% of older patients with DLBCL or cHL within two years after diagnosis and common cardiac comorbidities predict increased HF risk. Future studies incorporating baseline echocardiographic measures may improve model performance.
Authors
- Susan Kenyon Parsons (ORCID: https://orcid.org/0000-0003-0282-6490)
- David M. Kent (ORCID: https://orcid.org/0000-0002-9205-5070)
- Anita J. Kumar (ORCID: https://orcid.org/0000-0002-8704-0296)
- Jason Nelson
- Jonathan W. Friedberg (ORCID: https://orcid.org/0000-0002-1420-5563)
- Andrew M. Evens (ORCID: https://orcid.org/0000-0002-6900-1824)
- Jenica N. Upshaw (ORCID: https://orcid.org/0000-0001-5801-5481)
- Bonnie Ky
- Cara Guardino
- Marvin A Konstam
- Angie Mae Rodday
- Benjamin Sweigart
Institutions
- Tufts University (US)
- Tufts Medical Center (US)
- Beth Israel Deaconess Medical Center (US)
- University of Rochester Medical Center (US)
- Deaconess Hospital (US)
- Rutgers Cancer Institute (US)
- Tufts Clinical and Translational Science Institute (US)
- University of Rochester (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Cardio-Oncology
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1186/s40959-026-00593-w
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Cancer Institute